News

Yann-Alexandre Vano, MD, discusses some of the exciting data being seen in the renal cell carcinoma space.

Midway through the IMMUNOCERV trial, PDS0101 enhances the production of versatile CD8 killer T cells, leading to reduced tumor DNA and significant tumor shrinkage of over 60% in all patients with high-risk cervical cancer.

Top-line results from a phase 2b trial evaluating FG001 for patients with high-grade glioma are expected by the end of November.

Further development of 177Lu-satoreotide tetraxetan is expected after promising data from a phase 1/2 trial were recently published.

The classes of cellular immunotherapies and those blocking negative regulatory signals, known as immune checkpoint blockade, have revolutionized cancer treatment.

The phase 1/2 trial is evaluating 64Cu/67Cu SAR-Bombesin for diagnosis and treatment of castrate resistant prostate cancer.

The final analysis of the phase 2 ASPEN-06 is underway and expected to complete in 2024.

Marcia S. Brose, MD, PhD, FASCO, discusses the landscape of thyroid cancer by explaining the complexities and promising advancements seen in the space.

Based on the recommendation of an independent data monitoring committee and positive topline data, accrual in the KMT2A-rearranged cohorts of the AUGMENT-101 trial of revumenib will be stopped.

In an interview, Nathan Bahary, MD, PhD, explains what factors have contributed to the rise in oncology drug shortages, and emphasizes the importance of proactive measures moving forward, while also suggesting the importance of policy changes and increased communication.

The FDA and Takeda have decided to voluntarily withdraw mobocertinib, a drug for patients with EGFR exon20 insertion mutation-positive non–small cell lung cancer.

Phase 2 studies are investigating BDC-1001 in HER2-positive gastroesophageal, colorectal, breast, and endometrial cancers.

Liquid biopsy is offering a noninvasive, real-time, and personalized approach to tumor assessment, and is already revolutionizing the field of clinical oncology.

The fast track designation for AVB-001 granted by the FDA recognizes its potential as a treatment option for patients with relapsed/refractory ovarian cancer.

An MCGN drug combination shows potential to be more effective than standard chemotherapy alone for treatment-naïve metastatic pancreatic cancer.

Justin Taylor, MD, discusses the treatment landscape for chronic lymphocytic leukemia and background on his early research assessing NX-2127 for this patient population.

In an interview with Targeted Oncology, Tanya B. Dorff, MD, discussed the role of goserelin and LHRH antagonists in the ever-changing treatment landscape for patients with prostate cancer.

A recent phase 1/2 study revealed promising results, with an estimated 4-month intracranial progression-free survival rate of 70.7% with stereotactic radiosurgery with the combination of nivolumab and ipilimumab.

For large cell lymphomas, physicians typically use CT and positron emission tomography-computed tomography scans to look for signs of minimum residual disease when treatment is completed.

NXC-201 has demonstrated safety and elicited hematologic and organ responses in patients with relapsed/refractory amyloid light chain amyloidosis, including frail patients.

In the phase 3 CARTITUDE-4 trial, ciltacabtagene autoleucel was shown to be effective when used in patients with multiple myeloma exhibiting poor prognostic features.

In an interview with Targeted Oncology, Justin Taylor, MD, discussed early research on NX-2127, a BTK degrader being evaluated for the treatment of chronic lymphocytic leukemia.

IberVd showed high efficacy with deep, ongoing responses among older patients with transplant-ineligible, newly diagnosed multiple myeloma.

Researchers identified KDM6A’s role in CD38 regulation and found that an EZH2 inhibitor could potentially reduce resistance to an anti-CD38 antibody in multiple myeloma cells.

Although response rates were lower among patients given previous anti-BCMA therapy, teclistamab shows promise for all patients with relapsed/refractory multiple myeloma.

At a median duration of response of 12.2 months, the objective response rates with forimtamig across all dose levels was 66.7% with a very good partial response rate of 54.2%, according to data from a phase 1a dose-escalation trial.

In the non–small cell lung cancer space, identifying the appropriate candidate to receive perioperative approaches, such as neoadjuvant or adjuvant therapy, remains the clinical objective.

According to data presented at IMS 2023, a real-world analysis showed that teclistamab demonstrated comparable efficacy to the results observed in the phase 2 MajesTec-1 trial for patients with relapsed/refractory multiple myeloma.

The Dara-KRd regimen with double transplant induced deep response rates and a high minimal residual disease negativity rates among patients with high-risk, newly diagnosed multiple myeloma.

In an interview with Targeted Oncology, Yael Schenker, MD, MAS, FAAHPM, discussed the importance of palliative care and advanced care planning for patients with advanced cancers.